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simultaneously take into account the contribution of
specific clinical and therapeutic factors that could
potentially explain longer survival among women. To
better characterize sex differences, additional clinical
and therapeutic information was collected retrospec-
tively about patients undergoing surgery for non–small
cell lung carcinoma (NSCLC) in our institution over a
20-year period.
Patients and methods
Between January 1, 1977, and December 31, 1996, 1046
patients underwent thoracotomy for NSCLC in the Thoracic
Surgery Unit at the University Hospital of Geneva. According
to the population-based cancer registry, this institution recruit-
ed more than 85% of all NSCLCs treated by operation in the
canton of Geneva. Although no lung cancer–screening pro-
gram was performed over the 20-year period in Geneva, chest
radiography was usually performed for each new patient older
than 50 years on admission to the hospital.
The charts of all patients were retrospectively reviewed, and
data on patient age, preoperative symptoms, bronchoscopy
findings, tobacco use in pack-years, type of surgical proce-
dures, histologic type, stage of disease, adjuvant therapy, post-
operative complications, and long-term outcome were
retrieved. Nine patients (all men) were excluded because of
incomplete documents.
A s observed in North America and in most countriesof northwestern Europe, lung cancer incidence has
markedly changed in Switzerland over the past 2
decades.1,2 The incidence (standardized for age) for
men increased until the 1980s and then started to
decline. In contrast, lung cancer incidence among Swiss
women, which is much lower than that for men, started
to increase later and is still on the rise.
Several authors have reported a more favorable prog-
nosis of lung cancer in women than in men.3-6 In par-
ticular, we recently reported, from a population-based
study performed in Geneva, that sex strongly influences
the long-term survival expectancy independently of the
effect of other widely known prognostic factors.7
However, this study, as well as others, was unable to
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SEX DIFFERENCES IN PRESENTATION, MANAGEMENT, AND PROGNOSIS OF PATIENTS WITH
NON–SMALL CELL LUNG CARCINOMA
For patients resident in the canton, follow-up information
was obtained from the Geneva Cancer Registry, as described
previously.8 Briefly, in addition to passive follow-up (ie, rou-
tine examination of death certificates and of incidental find-
ings in hospital records), active follow-up was carried out
systematically by consulting the files of the Cantonal
Population Office for all living patients at successive 5-year
intervals after the incidence date. For the present study, the
registry performed additional follow-up for patients operated
on after January 1, 1993, to update the files up to January 1,
1998. For nonresident cases, follow-up information was
obtained from hospital charts or phone calls to family physi-
cians. Information on vital status was missing in 44 nonresi-
dent patients who were therefore excluded from survival
analysis.
At initial presentation in the thoracic surgery unit, all
patients were routinely and prospectively evaluated with a
thorough medical history, physical examination, complete
blood cell count, and blood chemistry and liver function tests.
Chest radiography was systematically performed. In addition,
computed tomographic (CT) scans of the chest and upper part
of the abdomen were routinely performed since 1984. Bone
scintigraphy and brain CT scan were obtained if indicated by
clinical examination, abnormal laboratory values, or both.
When enlarged mediastinal lymph nodes (15 mm or more in
the largest diameter) were detected on CT scanning, medi-
astinoscopy was included in the standard preoperative evalu-
ation process. If mediastinal lymph nodes were found to be
metastatic, patients were usually excluded from operations.
The diagnosis of lung infection was made on the basis of the
presence of fever, purulent sputum, and/or a new infiltrate on
chest x-ray film requiring antibiotic treatment. Ex-smokers
were defined as patients who had stopped smoking before the
diagnosis of lung carcinoma, regardless of the lapse of time
since smoking arrest.
The type of resection was primarily dictated by the local
extent of the tumor and secondarily by the cardiorespiratory
function and general health status. All surgical procedures
were performed either by staff surgeons or by senior residents
under their direct supervision. With regard to pathologic stag-
ing of the tumor, patients underwent sampling of mediastinal
lymph nodes before 1992 and systematic mediastinal dissec-
tion thereafter. Operative mortality included 30-day mortality
rates, as well as any later deaths occurring during the initial
hospital stay. Histologic typing was conducted according to
the International Classification of Disease for Oncology.9
Tumor extent was determined postoperatively according to
the revised pTNM classification.10
Patients with positive mediastinal lymph node involvement
discovered postoperatively on histologic examination (pN2)
usually underwent postoperative chemoradiotherapy.
Radiotherapy was also given when the tumor cells infiltrated
the resection margins. Since 1995, patients with N1 disease
were included in an international randomized controlled trial
to assess the effectiveness of postoperative chemotherapy
(International Adjuvant Lung Cancer Trial). Induction thera-
py for N2 disease was initiated in 1997 and therefore was not
applied to this patient series.
Characteristics of both sex groups were compared with the
use of the χ2 or Student t test where necessary. Survival was
analyzed by the Kaplan-Meier method. Differences in sur-
vival were determined by using the log-rank test. Multivariate
Cox regression analysis11 was used to test the independent
effect of sex after accounting for age (<60, 60-69, and ≥70
years), preoperative symptoms (none, weight loss, and other
symptoms), smoking habits (0, ≤40, and >40 pack-years),
type of surgical procedures (exploratory thoracotomy, pneu-
monectomy, and lesser resections), histology (squamous cell,
adenocarcinoma, and other carcinomas), and stage of disease
(I, II, III, and IV). By using the Cox model, we excluded 8
patients who died the day of surgery. To test whether sex dif-
ferences differed according to a given tumor characteristic,
we performed interaction tests12 by introducing, in the model
interaction, terms involving sex and the characteristic of
interest considering the same variables of adjustment.
Results
The group included 839 men and 198 women aged
61 ± 9 years (mean ± SD; range, 27 to 89 years) and 62
± 10 years (range, 34 to 82 years), respectively (P = .8).
The proportion of women was higher in the group of
patients over 70 years (25% vs 19% in men, P = .04).
Modes of presentation differed significantly between
the two sexes (Table I). Weight loss, hemoptysis, tho-
racic pain, and lung infection were observed more fre-
quently in men. In contrast, the proportion of asympto-
matic tumors discovered on routine chest x-ray film
was higher in women (32% vs 20% in men, P = .006).
Data regarding smoking habits were available for
94% of patients. Most of the patients were current
smokers or ex-smokers at the time of their presentation.
However, the mean cigarette consumption was greater
in men than in women (52 ± 25 pack-years vs 31 ± 27
pack-years, respectively; P < .001), and women were
much more likely to have a negative smoking history
(27% vs 2% in men, P < .001). This difference holds
true in all types of NSCLC, although the proportion of
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Table I. Sex differences in the type of signs and
symptoms
Male subjects Female subjects 
Symptoms (n = 839) (n = 198) P value
None 153 (20%) 54 (32%) .006
Cough 84 (11%) 25 (15%) .3
Hemoptysis 242 (32%) 28 (17%) <.001
Thoracic pain 186 (25%) 28 (17%) .02
Lung infection 214 (28%) 32 (19%) .007
Weight loss 235 (31%) 39 (23%) .02
Unknown 84 (10%) 29 (15%) .08
nonsmokers was lower in women with squamous cell
carcinoma (16%).
Men had the majority of squamous cell carcinomas
(65% vs 31% in women, P < .0001), whereas adeno-
carcinoma predominated in women (54% vs 26% in
men, P < .0001; Table II). The percentage of bron-
choalveolar carcinoma was greater in women (9% vs
3% in men, P < .0001). Large cell and undifferentiated
carcinomas were evenly distributed in the two sexes.
Bronchoscopy was performed in 90% of men and
80% of women, and its contribution to preoperative
histologic diagnosis was higher in men than in women
(69% vs 49%, P < .001). In contrast, fine needle biop-
sy under fluoroscopy was performed more frequently
in women (17% vs 7% in men, P < .001). Before
surgery, the histologic diagnosis remained unknown in
26% of men and 43% of women (P < .001).
Lung tumors were predominantly located in the
upper lobes (56% in both men and women, not sig-
nificant). As shown in Table III, the proportion of
pneumonectomy was greater in men (32% vs 22% in
women, P = .01), whereas more women underwent
segmentectomy (11% vs 5% in men, P = .007). With
regard to tumor extension, a majority of patients had
tumors of stage IA and IB (Table IV). A seemingly
large proportion of patients underwent surgery for
stage IIIB (n = 93) and IV (n = 37) disease. This find-
ing is partly attributed to the new staging classification,
which considers 2 separate lung nodules in the same
lobe as T4 disease (stage IIIB) and 2 separate lung nod-
ules in different lobes as M1 disease (stage IV).
No difference was observed in the distribution of
adjuvant therapy between the two sex groups (25% in
men vs 23% in women, P = .4). In particular, 10 men
and no women received adjuvant chemotherapy
according to our protocol for N1 disease.
We observed a higher operative mortality rate in men
compared with women (7% vs 3%, respectively) both
after univariate analysis (P = .07) and after additional
analyses accounting for the effects of age and type of
surgery (P = .06).
The mean follow-up was similar between men and
women (48 and 44 months, respectively). In univariate
analysis the overall mean survival time was greater in
women than in men (30 months vs 24 months, respec-
tively; P = .005). This sex difference remained signifi-
cant in the adenocarcinoma histologic type (Table II)
and in the early tumoral stages (IA, IB, and IIB; Table
IV). The difference was not statistically significant in
stage IIA disease, most likely because of the small
number of patients with T1 N1 disease (n = 44).
The effect of each factor on the instantaneous mor-
tality rate estimated by multivariate analysis by using
the Cox model analysis is reported in Table V. Tumor
stage, presence of symptoms, smoking habits, and type
of surgery were significantly linked to prognosis.
Patients who lost weight carried a 1.87-fold increased
risk of death (95% confidence interval [CI], 1.46-2.40)
compared with asymptomatic patients. Smokers had a
significantly worse prognosis than nonsmokers (hazard
ratio, 1.67; 95% CI, 1.12-2.49). Although this smoking
effect was present for all histologic types, we observed
no significant differences between former and current
smokers (hazard ratio, 0.89; 95% CI, 0.62-1.29).
Compared with pneumonectomy, lesser resections
were associated with a trend toward a decreased risk of
death (hazard ratio, 0.86; 95% CI, 0.70-1.05), whereas
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Table II. Sex differences in histologic distribution and in mean survival time
Histologic distribution Mean survival (mo)*
Male subjects Female subjects Male subjects Female subjects 
Histology (n = 839) (n = 198) P value (n = 804) (n = 189) P value
All histologies 839 (100%) 198 (100%) <.001 24 30 .005
Squamous cell 543 (65%) 62 (31%) <.001 25 24 .7
Adenocarcinoma 217 (26%) 106 (54%) <.001 22 32 .01
Bronchoalveolar 26 (3%) 18 (9%) <.001 32 50 .3
Large cell 38 (4%) 9 (4%) .9 12.5 13 .7
Undifferentiated 15 (2%) 3 (2%) .9 15 24 .7
*Forty-four patients lost to follow-up were excluded from survival analysis.
Table III. Sex differences in surgical procedures
Male subjects Female subjects 
Surgery (n = 839) (n = 198) P value
All resections 839 (100%) 198 (100%) .003
Pneumonectomy 265 (32%) 44 (22%) .01
Bilobectomy 51 (6%) 8 (4%) .3
Lobectomy 431 (51%) 110 (55%) .3
Segmentectomy 43 (5%) 21 (11%) .007
Thoracotomy only 49 (6%) 15 (8%) .5
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Table IV. Sex differences in stage distribution and mean survival time
Stage distribution Mean survival (mo)*
Male subjects Female subjects Male subjects Female subjects 
Stage (n = 839) (n = 198) P value (n = 804) (n = 189) P value
IA 166 (20%) 39 (19%) .9 91 117 .04
IB 231 (28%) 44 (22%) .2 40 68 .02
IIA 36 (4%) 8 (4%) .9 26 66 .8
IIB 169 (20%) 33 (17%) .3 16 43 .01
IIIA 132 (16%) 49 (25%) .004 14 15 .7
IIIB 79 (9%) 14 (7%) .4 8 5 .8
IV 26 (3%) 11 (6%) .1 9 10 .9
*Forty-four patients lost to follow-up were excluded from survival analysis.
Table V. Effect of prognostic factors on instantaneous mortality rate
Variables No. Hazard ratio 95% CI P value
Age (y)
<60 431 1 Reference
60-69 373 1.2 1.02–1.41 .03
≥70 189 1.2 0.98–1.47 .08
After adjustment for age
Sex
Male 804 1 Reference
Female 189 0.75 0.62–0.91 .004
After adjustment for age and 
all other factors listed below
Symptoms
None 198 1 Reference
Weight loss 264 1.87 1.46–2.40 <.001
Other symptoms 404 1.21 0.95–1.53 .1
Smoking habits
0 pack-years 62 1 Reference
<40 pack-years 378 1.82 1.22–2.72 .004
>40 pack-years 494 1.48 0.99–2.21 .06
Type of surgery
Pneumonectomy 293 1 Reference
Lesser resections 636 0.86 0.70–1.05 .1
Exploratory thoracotomy 64 1.74 1.25–2.41 .001
Histology
Squamous cell 577 1 Reference
Adenocarcinoma 310 1.19 0.97–1.45 .09
Other carcinomas 106 1.35 1.02–1.77 .03
Stage
I 458 1 Reference
II 225 1.82 1.45–2.28 <.001
III and IV 310 3.06 2.45–3.82 <.001
Sex
Male 805 1 Reference
Female 189 0.72 0.56–0.92 .009
Combined effect of sex .04*
and stage 
Male and stage I, II 1 Reference
Female and stage I, II 0.59 0.43–0.83
Male and stage III, IV 2.07 1.67–2.57
Female and stage III, IV 2.02 1.42–2.86
Results are from a multivariate analysis with the Cox model. Patients lost to follow-up (n = 44) were excluded from analysis.
*χ2 interaction test after adjustment for age, symptoms, smoking habits, type of surgery, histology, stage, and sex.
exploratory surgery alone conferred a significant
excess of risk (hazard ratio, 1.74; 95% CI, 1.25-2.41),
reflecting the absence of putative curative surgery.
Women were found to have a better prognosis than
men independently of the effects of age, symptoms,
smoking habits, type of surgery, histology, and stage of
disease (hazard ratio, 0.72; 95% CI, 0.56-0.92; Table V). 
Significant interaction between sex and cancer stage
on NSCLC prognosis was observed (P = .04). The rel-
ative protection linked to female status was present in
early-stage carcinoma (stage I and II; hazard ratio,
0.59; 95% CI, 0.43-0.83), whereas it was absent (close
to one) in more advanced stages (stage III and IV, Table
V). None of the other interactions, such as those
between sex and histology (squamous cell, adenocarci-
noma, and other carcinomas), sex and tobacco (0, ≤40,
and >40 pack-year), and sex and age (<60, 60-69, and
≥70 years) were statistically significant.
Discussion
In this retrospective study on more than 1000 patients
undergoing lung resection for NSCLC, we observed
strong differences between the sexes in tumor presen-
tation, management, and prognosis.
Despite the large number of patients in the study,
only 198 (19%) were women, thus reflecting the male
preponderance of lung carcinoma in Geneva.13
However, this represents one of the largest surgical
series of women reported in the literature.
As we have previously reported during the 20-year
interval of the study, improved perioperative care, as
well as better staging modalities and refinements in
both medical and radiation oncology, improved the 5-
year survival.14 Nonetheless, patients in either sex
group were cared for equivalently, thus allowing valid
intergroup comparisons.
In this series we observed striking differences in
smoking habits between men and women. Whereas
over 25% of women were nonsmokers, this rate
remained at 2% in the male population. Furthermore,
the mean cigarette consumption was significantly
lower in smoking women than in men.
Such difference in smoking habits likely resulted in
different clinical presentation, histology, and treatment.
Squamous cell carcinoma was present in the majority
of men in our series (65%). Because these tumors are
well known to predominate in heavy smokers and to
develop from large and central bronchus,15,16 they are
often difficult to detect by chest radiography at early
stages because of the overlying hilar and mediastinal
structures. Hence a large majority of the male subjects
(80%) demonstrated clinical signs, such as hemoptysis,
lung infection, thoracic pain, or weight loss, by the
time of surgery, and 32% of them underwent pneu-
monectomy.
In women, adenocarcinoma accounted for the major-
ity of lung carcinoma (54%). Because these tumors are
usually located in the periphery of the lung, a greater
proportion of women were asymptomatic (32%).
Pneumonectomy was less frequently performed and
thus contributed to a lower operative mortality rate
compared with that found in the male subjects. These
data are consistent with those from the previous obser-
vations of Mitsudomi and colleagues17 in a group of
Japanese patients undergoing surgery for NSCLC.
In addition to the widely known prognostic factors,
such as stage and histologic characteristics,7 this study
showed that sex, weight loss, and smoking habits also
significantly influence the prognosis of NSCLC.
Better survival among women with lung carcinomas
has already been demonstrated in a few previous stud-
ies,3-7 but the reason why such a sex difference exists
remains obscure. Palomares and colleagues18 have
reported that weight loss was a significant prognostic
factor contributing to reduction of the long-term sur-
vival in men. Our study demonstrated that sex
remained an independent prognostic factor, even after
accounting for the different smoking distribution and
weight loss pattern between men and women. The sex
difference was also not explained by other differences
in lung cancer presentation and management. In addi-
tion, we observed that the effect of sex was present
only in early tumor stages.
These findings give further support to the hypothesis
that the hormonal status may influence the prognosis of
lung carcinoma. Indeed, the presence of estrogen
receptors has been demonstrated on human lung cancer
tissue,19-21 and these receptors, with their dependent
intracellular processes, differed among the various
types of lung carcinoma and stages of disease.22-24
Although the majority of women diagnosed with
lung carcinoma are postmenopausal with low levels of
circulating estrogens, reproductive hormones remain
the most fertile area to explore. In our series there was
no significant interaction between age and sex, and bet-
ter prognosis remained present in women before and
after the age of 50 years (data not shown).
Recently, the use of estrogen replacement therapy, as
well as short menstrual cycles and late menopause,
have been reported to increase the risk of lung adeno-
carcinoma in women.25,26 Further in vitro experiments
have shown that 2-methoxyestradiol, which is an
endogenous estrogen metabolite, suppressed tumor
growth by inhibiting angiogenesis and inducing apop-
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tosis in human lung cancer cell lines.27,28 These initial
results should strongly encourage additional studies on
the interaction between sex and lung tumor characteris-
tics to better clarify why and how sex could modify
lung carcinogenesis.
We thank Dr L. Raymond for reviewing the manuscript.
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